

07 January 2016

'RESEARCH NEVER STOPS'

info@evotec.com | www.evotec.com

For further information,  
please contact

**Gabriele Hansen**  
VP, Corporate Communications &  
Investor Relations  
+49.(0)40.560 81-255  
+49.(0)40.560 81-333 Fax  
gabriele.hansen@evotec.com

Evotec AG  
Manfred Eigen Campus  
Essener Bogen 7  
22419 Hamburg (Germany)

## Evotec and UCB sign multi-year sample management agreement

**Hamburg, Germany – 07 January 2016:** Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced an EVT Execute collaboration aimed at providing a complete solution to UCB's global sample management requirements.

Under the terms of the agreement, Evotec will manage UCB's compound collection out of its state-of-the-art sample management facility in Toulouse, France. The agreement covers an initial period of five years.

**Dr Mario Polywka, Chief Operating Officer of Evotec, stated:**

"We are delighted to expand our long standing and successful relationship with UCB through this collaboration designed to provide sample management infrastructure, logistics and expertise to support their drug discovery efforts. This collaboration will use the first-class team and best-in-class infrastructure from our Toulouse site which was acquired in April 2015."

**Dr Neil Weir, Senior Vice President of Discovery at UCB, commented:** "With Evotec's proven track record in compound management coupled with global operations and an outstanding team and facility in Toulouse, we are confident of the quality and scalability of the services our internal and external discovery teams will receive."

No financial details were disclosed.

### ABOUT UCB

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8500 people in approximately 40 countries, the company generated revenue of € 3.3 billion in 2014. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB\_news

### ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche

---

and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease. For additional information please go to [www.evotec.com](http://www.evotec.com).

---

**FORWARD LOOKING STATEMENTS** — *Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.*